Shortening duration of ertapenem in outpatient parenteral antimicrobial therapy for complicated urinary tract infections: A retrospective study

Autoři: Doug L. Fink aff001;  Steven Collins aff003;  Ronnie Barret aff003;  Gabriele Pollara aff001;  Michael Marks aff003;  Sarah Logan aff003
Působiště autorů: Department of Microbiology, University College London Hospital, London, United Kingdom aff001;  Division of Infection and Immunity, University College London, London, United Kingdom aff002;  Hospital for Tropical Diseases, University College London Hospital, London, United Kingdom aff003;  Clinical Research Department, Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine Hospital for Tropical Diseases, University College London Hospitals NHS Trust, London, United Kingdom aff004
Vyšlo v časopise: PLoS ONE 14(9)
Kategorie: Research Article
doi: 10.1371/journal.pone.0223130



The incidence of multi-drug resistant ESBL-associated urinary tract infections (UTIs) is increasing globally. Patients with abnormal renal tract anatomy and other co-morbidities are at increased risk of complicated UTI and ESBL-associated infections. The duration and safety of OPAT for this cohort of patients is unknown.


This study aims to provide an evidence base to support decision-making regarding duration of antibiotic treatment for complicated UTIs.


We retrospectively reviewed all patients receiving ertapenem with or without adjunctive fosfomycin for complicated UTIs in the OPAT service of our tertiary infectious diseases hospital. All data had been collected prospectively as part of routine clinical care. Our primary outcomes were microbiological and clinical cure of UTI.


We identified 33 treatment episodes of ertapenem use for UTIs. 76% episodes related to pyelonephritis or urosepsis diagnoses. Renal tract abnormalities or prior urological surgery were present in 45% of patients. The median duration of appropriate parenteral antibiotic therapy in our study was 6 days. Clinical cure was achieved with short-course parenteral treatment alone in 81% of patients and this increased to 96% when adjunctive fosfomycin was used. There was a single treatment failure resulting in hospital admission.


Short duration ertapenem via OPAT with or without adjunctive fosfomycin is safe and effective for the treatment of complicated UTIs. Further studies are required to inform optimal treatment strategies and publication of guidelines in this field.

Klíčová slova:

Antibiotics – Antimicrobial resistance – Antimicrobials – Nosocomial infections – Urinary tract infections – Treatment guidelines – Pyelonephritis – Urologic infections


1. Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother. 2007;60(5):913–20. doi: 10.1093/jac/dkm318 17848376

2. Lee S, Song DY, Cho SH, Kwon KT. Impact of extended-spectrum beta-lactamase on acute pyelonephritis treated with empirical ceftriaxone. Microb Drug Resist. 2014;20(1):39–44. doi: 10.1089/mdr.2013.0075 23941639

3. Chapman AL. Outpatient parenteral antimicrobial therapy. BMJ. 2013;346:f1585. doi: 10.1136/bmj.f1585 23532865

4. Toner L, Papa N, Aliyu SH, Dev H, Lawrentschuk N, Al-Hayek S. Extended-spectrum beta-lactamase-producing Enterobacteriaceae in hospital urinary tract infections: incidence and antibiotic susceptibility profile over 9 years. World J Urol. 2016;34(7):1031–7. doi: 10.1007/s00345-015-1718-x 26511749

5. Vardakas KZ, Tansarli GS, Rafailidis PI, Falagas ME. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum beta-lactamases: a systematic review and meta-analysis. J Antimicrob Chemother. 2012;67(12):2793–803. doi: 10.1093/jac/dks301 22915465

6. Trad MA, Zhong LH, Llorin RM, Tan SY, Chan M, Archuleta S, et al. Ertapenem in outpatient parenteral antimicrobial therapy for complicated urinary tract infections. J Chemother. 2017;29(1):25–9. doi: 10.1080/1120009X.2016.1158937 27239695

7. Senol S, Tasbakan M, Pullukcu H, Sipahi OR, Sipahi H, Yamazhan T, et al. Carbapenem versus fosfomycin tromethanol in the treatment of extended-spectrum beta-lactamase-producing Escherichia coli-related complicated lower urinary tract infection. J Chemother. 2010;22(5):355–7. doi: 10.1179/joc.2010.22.5.355 21123160

8. NICE. Multidrug resistant urinary tract infections: fosfomycin trometamol [Available from:

9. Rosso-Fernandez C, Sojo-Dorado J, Barriga A, Lavin-Alconero L, Palacios Z, Lopez-Hernandez I, et al. Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial. BMJ Open. 2015;5(3):e007363. doi: 10.1136/bmjopen-2014-007363 25829373

10. Matthews PC, Barrett LK, Warren S, Stoesser N, Snelling M, Scarborough M, et al. Oral fosfomycin for treatment of urinary tract infection: a retrospective cohort study. BMC Infect Dis. 2016;16(1):556. doi: 10.1186/s12879-016-1888-1 27729016

11. EUA. Urological Infections [cited 2018. Available from:

12. Eliakim-Raz N, Yahav D, Paul M, Leibovici L. Duration of antibiotic treatment for acute pyelonephritis and septic urinary tract infection—7 days or less versus longer treatment: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2013;68(10):2183–91. doi: 10.1093/jac/dkt177 23696620

13. Kyriakidou KG, Rafailidis P, Matthaiou DK, Athanasiou S, Falagas ME. Short- versus long-course antibiotic therapy for acute pyelonephritis in adolescents and adults: a meta-analysis of randomized controlled trials. Clin Ther. 2008;30(10):1859–68. doi: 10.1016/j.clinthera.2008.10.007 19014841

14. Yilmaz E, Akalin H, Ozbey S, Kordan Y, Sinirtas M, Gurcuoglu E, et al. Risk factors in community-acquired/onset urinary tract infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. J Chemother. 2008;20(5):581–5. doi: 10.1179/joc.2008.20.5.581 19028620

15. Park SH, Choi SM, Lee DG, Cho SY, Lee HJ, Choi JK, et al. Impact of extended-spectrum beta-lactamase production on treatment outcomes of acute pyelonephritis caused by escherichia coli in patients without health care-associated risk factors. Antimicrob Agents Chemother. 2015;59(4):1962–8. doi: 10.1128/AAC.04821-14 25583722

16. Teillant A, Gandra S, Barter D, Morgan DJ, Laxminarayan R. Potential burden of antibiotic resistance on surgery and cancer chemotherapy antibiotic prophylaxis in the USA: a literature review and modelling study. Lancet Infect Dis. 2015;15(12):1429–37. doi: 10.1016/S1473-3099(15)00270-4 26482597

17. Qureshi ZA, Syed A, Doi Y. Safety and efficacy of long-term outpatient ertapenem therapy. Antimicrob Agents Chemother. 2014;58(6):3437–40. doi: 10.1128/AAC.02721-14 24709258

18. Marks M, Pollara G, Miller D, Bhatt S, Reynolds C, Gant V, et al. elCID: An electronic Clinical Infection Database to support integrated clinical services and research in infectious diseases. J Infect. 2015;71(3):402–5. doi: 10.1016/j.jinf.2015.04.007 25892135

19. Underwood J, Marks M, Collins S, Logan S, Pollara G. Intravenous catheter-related adverse events exceed drug-related adverse events in outpatient parenteral antimicrobial therapy. J Antimicrob Chemother 2019; 74:787–790. doi: 10.1093/jac/dky474 30462237

20. Sawyer RG, Claridge JA, Nathens AB, Rotstein OD, Duane TM, Evans HL, et al. Trial of short-course antimicrobial therapy for intraabdominal infection. N Engl J Med. 2015;372(21):1996–2005. doi: 10.1056/NEJMoa1411162 25992746

Článek vyšel v časopise


2019 Číslo 9

Nejčtenější v tomto čísle

Tomuto tématu se dále věnují…


Zvyšte si kvalifikaci online z pohodlí domova

Antiseptika a prevence ve stomatologii
nový kurz
Autoři: MUDr. Ladislav Korábek, CSc., MBA

Citikolin v neuroprotekci a neuroregeneraci: od výzkumu do klinické praxe nejen očních lékařů
Autoři: MUDr. Petr Výborný, CSc., FEBO

Zánětlivá bolest zad a axiální spondylartritida – Diagnostika a referenční strategie
Autoři: MUDr. Monika Gregová, Ph.D., MUDr. Kristýna Bubová

Diagnostika a léčba deprese pro ambulantní praxi
Autoři: MUDr. Jan Hubeňák, Ph.D

Význam nemocničního alert systému v době SARS-CoV-2
Autoři: doc. MUDr. Helena Lahoda Brodská, Ph.D., prim. MUDr. Václava Adámková

Všechny kurzy
Kurzy Doporučená témata